Clinical Trial

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of obudanersen in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2025-03-31; most recent amendment 2026-06-22.
Status change: Not Yet Recruiting → Recruiting 2025-05-01
Trial Details
NCT Number NCT06914609
Lead Sponsor Ionis Pharmaceuticals, Inc.
Conditions Angelman Syndrome
Enrollment 158 participants
Start Date 2025-06-10
Primary Completion 2027-08 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-12